Bile duct cancer, Biliary tree cancers, Secondary cancers
Results
Phase 2
This study looked at a drug called derazantinib for bile duct cancer. You pronounce derazantinib as de-ra-zan-ti-nib.
It was for people with bile duct cancer that:
had started inside the liver. This is called intrahepatic bile duct cancer.
had spread
had certain changes in the FGFR2
The study was open for people to join between 2017 and 2022. The team presented the results at a conference in 2022 and put them online in 2023.
Recruitment start: 10 November 2017
Recruitment end: 17 May 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Jeff Evans
Basilea
Last reviewed: 08 May 2024
CRUK internal database number: 17246
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
